GENFIT (NASDAQ:GNFT) Earns Sell (D) Rating from Weiss Ratings

Key Points

• GENFIT's stock has been restated with a "sell (d)" rating by Weiss Ratings, indicating a bearish outlook from analysts.
• HC Wainwright has lowered its price target for GENFIT from $9.00 to $7.00 while maintaining a "buy" rating, resulting in a mixed sentiment among analysts.
• GENFIT shares traded down to $3.99, showing a notable decline and reflecting a broader trend with a low of $2.55 and a high of $6.42 over the past year.

GENFIT (NASDAQ:GNFT - Get Free Report)'s stock had its "sell (d)" rating restated by stock analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright decreased their price target on GENFIT from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday, September 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $7.00.

GENFIT Price Performance

NASDAQ:GNFT traded down $0.27 during mid-day trading on Tuesday, reaching $3.99. 5,487 shares of the stock were exchanged, compared to its average volume of 8,348. The business has a fifty day moving average price of $4.01 and a 200 day moving average price of $3.93. GENFIT has a 1-year low of $2.55 and a 1-year high of $6.42. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.74 and a quick ratio of 3.74.

Institutional Investors Weigh In On GENFIT

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC purchased a new position in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is currently owned by institutional investors.

GENFIT Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.